Kymera IPO Presentation Deck slide image

Kymera IPO Presentation Deck

Jo KYMERA Whole-Body Toolbox Ternary Complex Modeling Quantitative System Model Proprietary Chemistry Utilize comprehensive strategies for identification of starting ligands that bind to E3 ligases and proteins of interest Identify compounds with preferred physiochemical properties conducive to achieving the optimized target product profile • In silico drug discovery to accelerate hit finding and optimization Readily accessible and diverse library of preferred linkers to connect binders to the E3 ligase and the target Enables rational degrader design and optimization, and ability to improve molecular properties Characteristic V Pegasus Proprietary Chemistry Potency Human in vitro clearance Membrane permeability In vivo clearance Bioavailability Metric Whole Blood IRAK4 DC (nM) HLM (mL/min/mg) Permeability (A/B; x10 cm/s) Mouse CL (mL/min/kg) Mouse PO PK (%F) Compound A (1 Generation) 280 96 0.4 177 Compound B (2nd Generation) 17 3 <-15 40
View entire presentation